SHILPAMED — Shilpa Medicare Share News
0.000.00%
Last trade - 00:00- IN₹184.31bn
- IN₹189.99bn
- IN₹15.39bn
Brief: Shilpa Medicare Says CDMO Customer Receives Fast-Track Designation For Its Investigational Drug Candidate
India's Shilpa Medicare up after unit gets suitability certificate for API
Brief: Shilpa Medicare Says Unit Got Certificate Of Suitability From EDQM For API, Desmopressin
India's Shilpa Medicare hits record high on Antique Stock Broking 'buy' rating
Brief: Amneal And Shilpa Announce U.S. FDA Approval Of Boruzu™
Brief: Shilpa Medicare Submits NDA To US FDA By Unicycive
India's Shilpa Medicare surges to nearly 8-year high on successful drug trial
Successful Outcome Of Phase 3 Studies Of SMLNUD07 - Norudca
India's Shilpa Medicare jumps on completing clinical trial of albumin drug
Brief: Shilpa Medicare Completes Phase 1 Clinical Trial For Recombinant Human Albumin 20%
Brief: Shilpa Medicare Says Shilpa Pharma Lifesciences, Unit 2 Clears Cofepris-Mexico GMP Inspection
Brief: Shilpa Medicare Says Shilpa Biologics Gets Market Approval For Adalimumab 40 Mg/0.4 Ml Solution For Injection In Morocco
Brief: Shilpa Medicare's Unit 2 In Raichur Clears Anvisa-Brazil Gmp Inspection
India's Shilpa Medicare rises on positive results from drug trial
Brief: Shilpa Medicare Says USFDA Inspection At Hyderabad Facility Closed With Zero 483 Observations
India's Shilpa Medicare rises after unit submits drug master file to USFDA
Brief: Shilpa Medicare Says Unit Filed Drug Master File Of Recombinant Human Albumin 20% With USFDA
India's Shilpa Medicare rises after reporting profit in Q4
Brief: Shilpa Medicare Posts Profit In March-Quarter